Life Sciences

Overview


Chambers USA 2021

Whether you’re a cutting-edge medical device startup or a global biopharma leader, it’s mission that drives you. Amid pricing and payor pressures, regulatory scrutiny, emerging innovations and challenging pipelines, market demand continues to grow. To broaden your field of vision as you navigate this dynamic industry, you need integrated, global counsel that can help clear your path to success.

McDermott’s Life Sciences Team will get you closer to your goals. Composed of top lawyers with demonstrated strength across intellectual property, regulatory, transactional and litigation law, we’re a purpose-built team of thought leaders united by a passion for our work. Our team can meet the legal needs of life sciences companies at every stage of development. For decades, we have embraced the value of focused knowledge, harnessing both the particular skills of individuals and the collective experience of our team. This makes us uniquely qualified to help you move business initiatives across the finish line when it matters and anticipate what’s next.

Show More

Results


  • McDermott represented Themis, an Austria-based company focused on vaccines and immune-modulation therapies for infectious diseases and cancer, in its entering into a definitive agreement to be acquired by Merck (NYSE: MRK), a US-based pharmaceutical companies (known as MSD outside the US and Canada). Upon completion of the deal, Themis will become a wholly-owned subsidiary of Merck. The planned acquisition builds upon an ongoing collaboration between the two companies to develop vaccine candidates using the measles virus vector platform and is expected to accelerate the development of Themis’ COVID-19 vaccine candidate.
  • McDermott represented EPiX Therapeutics, Inc., a privately-held medical device company, in its sale to Medtronic plc (NYSE: MDT), one of the world’s largest medical device companies.
  • The McDermott team secured a jury verdict win for Firm client Amgen (NYSE: AMGN) in its long-fought battle with Sanofi and Regeneron Pharmaceuticals. The Delaware jury upheld the validity of two Amgen patents that cover PCSK9 antibody therapeutics, which help reduce low-density lipoproteins (LDL) or “bad” cholesterol. This is the team’s second win in the case, following remand after the first jury trial win in 2016 and an appeal to the Federal Circuit Court of Appeals.
  • McDermott represented Innate Pharma on a $1.2 billion partnering agreement with AstraZeneca (NYSE: AZN)
  • McDermott developed market pathway and FDA engagement strategies for a clinical laboratory for laboratory developed tests (LDTs), companion diagnostics and other products under FDA’s evolving regulatory paradigm for personalized medicine
  • McDermott advised Ampersand Capital Partners in its cross-border investment in Canopy Biosciences and simultaneous acquisition of Zellkraftwerk
  • McDermott represented one of China’s leading pharmaceutical company in a series of its investment and acquisition projects, including its outbound investment in the Middle East, complex milestone investments and biotech start-ups. The projects have involved several orphan drugs in the pipeline.

Show More

People


McDermott’s Life Sciences Team will get you closer to your goals. Composed of top lawyers with demonstrated strength across intellectual property, regulatory, transactional and litigation law, we’re a purpose-built team of thought leaders united by a passion for our work.